Skip to main content
TipRanks
Go Ultimate75% OFF

Kyntra Bio (0IL8) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Kyntra Bio has a market cap or net worth of $7.90M. The enterprise value is $8.64M.

Market Cap
$7.90M
Enterprise Value
$8.64M

Share Statistics

Kyntra Bio has 4,049,985 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
4,049,985
Owned by Insiders
3.43%
Owned by Institutions
38.78%

Financial Efficiency

Kyntra Bio’s return on equity (ROE) is -6.11 and return on invested capital (ROIC) is -50.72%.

Return on Equity (ROE)
-6.11
Return on Assets (ROA)
1.53
Return on Invested Capital (ROIC)
-50.72%
Return on Capital Employed (ROCE)
-0.51
Revenue Per Employee
189.41K
Profits Per Employee
5.40M
Employee Count
34
Asset Turnover
0.05
Inventory Turnover
0.15

Valuation Ratios

The current PE Ratio of Kyntra Bio is 0.21. Kyntra Bio’s PEG ratio is 0.00.

PE Ratio
0.21
PS Ratio
1.40
PB Ratio
-0.25
Price to FCF
-0.15
Price to Operating Cash Flow
-0.15
PEG Ratio
0.00

Income Statement

In the last 12 months, Kyntra Bio had revenue of 6.44M and earned 183.45M in profits. Earnings per share was 45.37.

Revenue
6.44M
Gross Profit
5.88M
Operating Income
-45.90M
Pretax Income
-58.29M
Net Income
183.45M
EBITDA
-57.55M
Earnings Per Share (EPS)
45.37

Cash Flow

In the last 12 months, operating cash flow was -38.05M and capital expenditures -9,000, giving a free cash flow of -38.06M billion.

Operating Cash Flow
-38.05M
Free Cash Flow
-38.06M
Free Cash Flow per Share
-11.97

Dividends & Yields

Kyntra Bio pays an annual dividend of $0.29, resulting in a dividend yield of ―

Dividend Per Share
$0.29
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-660.95%
Earnings Yield
475.84%

Stock Price Statistics

Beta
0.48
52-Week Price Change
-78.06%
50-Day Moving Average
5.65
200-Day Moving Average
6.82
Relative Strength Index (RSI)
15.07
Average Volume (3m)
1,663

Important Dates

Kyntra Bio upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 16, 2026
Next Earnings Date
Mar 01, 2027
Ex-Dividend Date
Mar 15, 2022

Financial Position

Kyntra Bio as a current ratio of 3.39, with Debt / Equity ratio of 0.00%

Current Ratio
3.39
Quick Ratio
3.26
Debt to Market Cap
0.00
Net Debt to EBITDA
0.83
Interest Coverage Ratio
-5.24

Taxes

In the past 12 months, Kyntra Bio has paid -90.00K in taxes.

Income Tax
-90.00K
Effective Tax Rate
0.00

Enterprise Valuation

Kyntra Bio EV to EBITDA ratio is -0.15, with an EV/FCF ratio of -0.26.

EV to Sales
2.34
EV to EBITDA
-0.15
EV to Free Cash Flow
-0.26
EV to Operating Cash Flow
-0.26

Balance Sheet

Kyntra Bio has $91.32M in cash and marketable securities with $0.00 in debt, giving a net cash position of $91.32M billion.

Cash & Marketable Securities
$91.32M
Total Debt
$0.00
Net Cash
$91.32M
Net Cash Per Share
$22.55
Tangible Book Value Per Share
-$2.01

Margins

Gross margin is 19.59%, with operating margin of -1099.92%, and net profit margin of 657.67%.

Gross Margin
19.59%
Operating Margin
-1099.92%
Pretax Margin
-332.10%
Net Profit Margin
657.67%
EBITDA Margin
-1533.75%
EBIT Margin
-1534.28%

Analyst Forecast

The average price target for Kyntra Bio is $22.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$22.75
Price Target Upside
1118.53% Upside
Analyst Consensus
Strong Buy
Analyst Count
5
Revenue Growth Forecast
-36.10%
EPS Growth Forecast
-110.80%